A Pilot Phase II Study of Maintenance Cabozantinib Plus Pembrolizumab for Patients With Metastatic Squamous Non-Small Cell Lung Cancer (sqNSCLC)
for Metastatic Squamous Non-Small Cell Lung Carcinoma
Drug: Cabozantinib
1 location in Chicago
Sponsor: University of Illinois at Chicago
Sex: All·Age: 18+
Code: NCT05613413·Phase 2·Recruiting